Transplantation of mesenchymal stem cells for the treatment of demyelinating diseases

Cell and Organ Transplantology. 2021; 9(1):60-65.
DOI: 10.22494/cot.v9i1.123

Transplantation of mesenchymal stem cells for the treatment of demyelinating diseases

Petriv T.^1,2,3, Tatarchuk M.¹, Tsymbaliuk Yu.¹, Tsymbaliuk V.⁴

¹Romodanov State Institute of Neurosurgery, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
²Medical Center Hemafund LTD, Kyiv, Ukraine
³QR Health Solutions, Kyiv, Ukraine
⁴National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Abstract

Demyelinating diseases, especially multiple sclerosis (MS) is not only medical but also socio-economic issue. Unsatisfactory quality of life and high degree of disability in these patients require the implementation of the advanced treatments, such as stem cell transplantation. Numerous experimental and clinical studies are being conducted, revealing new mechanisms of the action of stem cells in demyelinating diseases. Further research is needed to understand many more aspects of clinical use.
This review is devoted to the use of regenerative cell technologies in the treatment of demyelinating diseases, the current state and prospects of the approach to the treatment of such pathology with stem cells.

Keywords: stem cells; cell transplantation; multiple sclerosis

Full Text PDF

References

1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018; 391(10130):1622-1636. DOI: 10.1016/S0140-6736(18)30481-1. https://doi.org/10.1016/S0140-6736(18)30481-1

2. Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis – etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017; 71(0):551-563. DOI: 10.5604/01.3001.0010.3836 https://doi.org/10.5604/01.3001.0010.3836 PMid:28665284

3. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018; 31(6):752-759. DOI:10.1097/WCO.0000000000000622. https://doi.org/10.1097/WCO.0000000000000622 PMid:30300239

4. Axisa PP, Hafler DA. Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol. 2016; 29(3):345-353. DOI: 10.1097/WCO.0000000000000319 https://doi.org/10.1097/WCO.0000000000000319 PMid:27058221 PMCid:PMC7882195

5. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017; 140(3):527-546. DOI: 10.1093/brain/aww258. https://doi.org/10.1093/brain/aww258 PMid:27794524

6. Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: A comprehensive review. J Autoimmun. 2015; 64:13-25. DOI:10.1016/j.jaut.2015.06.010. https://doi.org/10.1016/j.jaut.2015.06.010 PMid:26142251 PMCid:PMC4687745

7. Goris A, Dubois B. Leveraging human genetics to inform intervention strategies for multiple sclerosis. Neurology. 2019; 92(16):735-736. DOI: 10.1212/WNL.0000000000007298. https://doi.org/10.1212/WNL.0000000000007298 PMid:30894451

8. Canto E, Oksenberg JR. Multiple sclerosis genetics. Mult Scler. 2018; 24(1):75-79. DOI: 10.1177/1352458517737371. https://doi.org/10.1177/1352458517737371 PMid:29307290

9. Yamout BI, Alroughani R. Multiple Sclerosis. Semin Neurol. 2018; 38(2):212-225. DOI: 10.1055/s-0038-1649502. https://doi.org/10.1055/s-0038-1649502 PMid:29791948

10. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015; 15(9):545-558. DOI: 10.1038/nri3871. https://doi.org/10.1038/nri3871 PMid:26250739

11. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018; 97(4):742-768. DOI:10.1016/j.neuron.2018.01.021. https://doi.org/10.1016/j.neuron.2018.01.021 PMid:29470968

12. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015; 5(9):e00362. DOI: 10.1002/brb3.362. https://doi.org/10.1002/brb3.362 PMid:26445701 PMCid:PMC4589809

13. Sospedra M, Martin R. Immunology of Multiple Sclerosis. Semin Neurol. 2016; 36(2):115-127. DOI: 10.1055/s-0036-1579739. https://doi.org/10.1055/s-0036-1579739 PMid:27116718

14. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015; 14(4):406-419. DOI: 10.1016/S1474-4422(14)70305-9. https://doi.org/10.1016/S1474-4422(14)70305-9

15. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016; 354:i3518. DOI: 10.1136/bmj.i3518. https://doi.org/10.1136/bmj.i3518 PMid:27549763

16. Douvaras P, Wang J, Zimmer M, et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Reports. 2014; 3(2):250-259. DOI:10.1016/j.stemcr.2014.06.012. https://doi.org/10.1016/j.stemcr.2014.06.012 PMid:25254339 PMCid:PMC4176529

17. Scolding NJ, Pasquini M, Reingold SC, et al. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017; 140(11):2776-2796. DOI:10.1093/brain/awx154. https://doi.org/10.1093/brain/awx154 PMid:29053779 PMCid:PMC5841198

18. Lee CC, Hirasawa N, Garcia KG, Ramanathan D, Kim KD. Stem and progenitor cell microenvironment for bone regeneration and repair. Regen Med. 2019; 14(7):693-702. DOI: 10.2217/rme-2018-0044. https://doi.org/10.2217/rme-2018-0044 PMid:31393221

19. Gonzales-Portillo GS, Sanberg PR, Franzblau M, et al. Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier. Cell Transplant. 2014; 23(4-5):531-539. DOI: 10.3727/096368914X678337. https://doi.org/10.3727/096368914X678337 PMid:24480552 PMCid:PMC4083632

20. Ullah M, Liu DD, Thakor AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019; 15:421-438. DOI:10.1016/j.isci.2019.05.004. https://doi.org/10.1016/j.isci.2019.05.004 PMid:31121468 PMCid:PMC6529790

21. Aisenbrey EA, Bryant SJ. A MMP7-sensitive photoclickable biomimetic hydrogel for MSC encapsulation towards engineering human cartilage. J Biomed Mater Res A. 2018; 106(8):2344-2355. DOI:10.1002/jbm.a.36412. https://doi.org/10.1002/jbm.a.36412 PMid:29577606 PMCid:PMC6030485

22. Shao PL, Wu SC, Lin ZY, Ho ML, Chen CH, Wang CZ. Alpha-5 Integrin Mediates Simvastatin-Induced Osteogenesis of Bone Marrow Mesenchymal Stem Cells. Int J Mol Sci. 2019; 20(3):506. DOI: 10.3390/ijms20030506. https://doi.org/10.3390/ijms20030506 PMid:30682874 PMCid:PMC6387019

23. Todeschi MR, El Backly R, Capelli C, et al. Transplanted Umbilical Cord Mesenchymal Stem Cells Modify the In Vivo Microenvironment Enhancing Angiogenesis and Leading to Bone Regeneration. Stem Cells Dev. 2015; 24(13):1570-1581. DOI:10.1089/scd.2014.0490. https://doi.org/10.1089/scd.2014.0490 PMid:25685989 PMCid:PMC4499786

24. de Witte SFH, Luk F, Sierra Parraga JM, et al. Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. Stem Cells. 2018; 36(4):602-615. DOI:10.1002/stem.2779. https://doi.org/10.1002/stem.2779 PMid:29341339

25. Munir H, Ward LSC, McGettrick HM. Mesenchymal Stem Cells as Endogenous Regulators of Inflammation. Adv Exp Med Biol. 2018; 1060:73-98. DOI: 10.1007/978-3-319-78127-3_5. https://doi.org/10.1007/978-3-319-78127-3_5 PMid:30155623

26. Regmi S, Pathak S, Kim JO, Yong CS, Jeong JH. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: Challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019; 98(5-8):151041. DOI:10.1016/j.ejcb.2019.04.002. https://doi.org/10.1016/j.ejcb.2019.04.002 PMid:31023504

27. Caplan AI, Sorrell JM. The MSC curtain that stops the immune system. Immunol Lett. 2015; 168(2):136-139. DOI: 10.1016/j.imlet.2015.06.005. https://doi.org/10.1016/j.imlet.2015.06.005 PMid:26079607

28. Selich A, Ha TC, Morgan M, et al. Cytokine Selection of MSC Clones with Different Functionality. Stem Cell Reports. 2019; 13(2):262-273. DOI:10.1016/j.stemcr.2019.06.001. https://doi.org/10.1016/j.stemcr.2019.06.001 PMid:31303506 PMCid:PMC6700478

29. Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett. 2015; 168(2):140-146. DOI:10.1016/j.imlet.2015.05.004. https://doi.org/10.1016/j.imlet.2015.05.004 PMid:25982165

30. Zhang Q, Fu L, Liang Y, et al. Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation. J Cell Physiol. 2018; 233(9):6832-6840. DOI:10.1002/jcp.26436. https://doi.org/10.1002/jcp.26436 PMid:29336475

31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4):1815-1822. DOI: 10.1182/blood-2004-04-1559. https://doi.org/10.1182/blood-2004-04-1559 PMid:15494428

32. Bonig H, Kuçi Z, Kuçi S, et al. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”-Outcome Report of 92 Patients. Cells. 2019; 8(12):1577. DOI:10.3390/cells8121577. https://doi.org/10.3390/cells8121577 PMid:31817480 PMCid:PMC6952775

33. Quintiliano K, Crestani T, Silveira D, et al. Neural Differentiation of Mesenchymal Stem Cells on Scaffolds for Nerve Tissue Engineering Applications. Cell Reprogram. 2016; 18(6):369-381. DOI:10.1089/cell.2016.0024. https://doi.org/10.1089/cell.2016.0024 PMid:27906586

34. Cuascut FX, Hutton GJ. Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives. Biomedicines. 2019; 7(2):26. DOI: 10.3390/biomedicines7020026. https://doi.org/10.3390/biomedicines7020026 PMid:30935074 PMCid:PMC6631931

35. Akinola Samuel Toluvani. Khіrurgіchna korektsіya demієlіnіzuyuchikh ushkodzhen’ tsentral’noї nervovoї sistemi іz zastosuvannyam mezenkhіmal’nikh stovburovikh klіtin (eksperimental’ne doslіdzhennya) [Surgical correction of demyelinating lesions of the central nervous system by using mesenchymal stem cells (experimental study)]. Aavtoref. dis. … kand. med. nauk – Dissertation abstract: 14.01.05. Kyiv, 2019. 27 p.[in Ukrainian]

36. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015; 2015:394917. DOI: 10.1155/2015/394917. https://doi.org/10.1155/2015/394917 PMid:25961059 PMCid:PMC4417567

37. Liu XD, Liu D, Zang CB, et al. IFN-γ stimulation enhances immunosuppressive capability of human umbilical cord mesenchymal stem cells. Europe PMC. 2014; 22(3):605-611. DOI:10.7534/j.issn.1009-2137.2014.03.006.

38. Miller RH, Bai L, Lennon DP, Caplan AI. The potential of mesenchymal stem cells for neural repair. Discov Med. 2010; 9(46):236-242.

39. Nessler J, Bénardais K, Gudi V, et al. Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS One. 2013; 8(7):e69795. DOI:10.1371/journal.pone.0069795. https://doi.org/10.1371/journal.pone.0069795 PMid:23922802 PMCid:PMC3724887

40. Li T, Xia M, Gao Y, Chen Y, Xu Y. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther. 2015; 15(9):1293-1306. DOI:10.1517/14712598.2015.1051528. https://doi.org/10.1517/14712598.2015.1051528 PMid:26067213

41. Liu R, Zhang Z, Lu Z, et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev. 2013; 22(7):1053-1062. doi:10.1089/scd.2012.0463. https://doi.org/10.1089/scd.2012.0463 PMid:23140594

42. Sahraian MA, Mohyeddin Bonab M, Baghbanian SM, Owji M, Naser Moghadasi A. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection. Immunol Invest. 2019; 48(2):160-168. DOI:10.1080/08820139.2018.1504301. https://doi.org/10.1080/08820139.2018.1504301 PMid:30156938

43. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010; 67(10):1187-1194. DOI:10.1001/archneurol.2010.248. https://doi.org/10.1001/archneurol.2010.248 PMid:20937945 PMCid:PMC3036569

44. Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020; 143(12):3574-3588. DOI:10.1093/brain/awaa333. https://doi.org/10.1093/brain/awaa333 PMid:33253391

45. Harris VK, Stark J, Vyshkina T, et al. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018; 29:23-30. DOI:10.1016/j.ebiom.2018.02.002/ https://doi.org/10.1016/j.ebiom.2018.02.002 PMid:29449193 PMCid:PMC5925446

46. Hosseini Shamili F, Alibolandi M, Rafatpanah H, et al. Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward mylein as a platform for reducing multiple sclerosis clinical score. J Control Release. 2019; 299:149-164. DOI:10.1016/j.jconrel.2019.02.032. https://doi.org/10.1016/j.jconrel.2019.02.032 PMid:30807806

47. Riordan NH, Morales I, Fernández G, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018; 16(1):57. DOI:10.1186/s12967-018-1433-7/ https://doi.org/10.1186/s12967-018-1433-7 PMid:29523171 PMCid:PMC5845260

48. Uccelli A, Laroni A, Brundin L, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019; 20(1):263. DOI: 10.1186/s13063-019-3346-z. https://doi.org/10.1186/s13063-019-3346-z PMid:31072380 PMCid:PMC6507027

49. Harris VK, Stark J, Vyshkina T, et al. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018; 29:23-30. DOI:10.1016/j.ebiom.2018.02.002. https://doi.org/10.1016/j.ebiom.2018.02.002 PMid:29449193 PMCid:PMC5925446

50. Available: https://clinicaltrials.gov

51. Yang H, Sun J, Wang F, Li Y, Bi J, Qu T. Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture – a preliminary study. Oncotarget. 2016; 7(45):72537-72545. DOI:10.18632/oncotarget.12345. https://doi.org/10.18632/oncotarget.12345 PMid:27705922 PMCid:PMC5341927

52. Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med. 2013; 13(5):856-867. DOI:10.2174/1566524011313050016. https://doi.org/10.2174/1566524011313050016 PMid:23642066

53. Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular Mechanisms Responsible for Therapeutic Potential of Mesenchymal Stem Cell-Derived Secretome. Cells. 2019; 8(5):467. DOI:10.3390/cells8050467 https://doi.org/10.3390/cells8050467 PMid:31100966 PMCid:PMC6562906

How to cite

Petriv T, Tatarchuk M, Tsymbaliuk Yu, Tsymbaliuk V. Transplantation of mesenchymal stem cells for the treatment of demyelinating diseases. Cell Organ Transpl. 2021; 9(1):60-65. doi:10.22494/cot.v9i1.123

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.